LLY vs SHC
Eli Lilly and Company vs Sotera Health — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
56
Buy
VS
| Metric | LLY | SHC |
|---|
| AI Score |
56
|
67
|
| Price |
$1,238.69
|
$19.50
|
| P/E Ratio |
41.81×
|
33.44×
|
| ROE |
77.8%
|
12.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.0%
|
54.7%
|
| Debt / Equity |
1.62×
|
3.41×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
59.0
|
59.0
|
| Beta |
0.506
|
1.775
|
| Expected Upside |
+0.1%
|
+1.1%
|
AI Committee View
Current Innellis committee reasoning for LLY versus SHC.
SHC leads by 11 points.
SHC scores 67/100 (Buy) versus LLY at 56/100 (Buy).
LLY Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 92.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
- EPS growing 94.6% YoY — Growth
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Price-to-book of 38.3x prices in significant intangible value — Value
- Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value
SHC Committee View
100% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is sector concentration is already high (hhi 3063.01). The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- RSI at 74 is in overbought territory — Technical
- Weekly RSI at 76 -- overbought on the larger timeframe too — Technical